L-arginine salt of BPC-157 pentadecapeptide / tissue-repair

Pentadeca Arginate

CAS: 137525-51-0 MW: 1419.5 Da (free peptide) Formula: C₆₂H₉₈N₁₆O₂₂ (free peptide)

Key Takeaways

  • Pentadeca Arginate is the L-arginine salt of the BPC-157 pentadecapeptide (sequence GEPPPGKPADDAGLV); no distinct CAS, INN, or peer-reviewed publication treats it as a separate chemical entity, and the only registered Phase 1 study on the underlying peptide (NCT02637284, 2015 Tijuana) has never reported results.
  • Investigational only; no FDA, EMA, MHRA, TGA, Health Canada, PMDA, NMPA, MFDS, or GRLS approval. FDA placed BPC-157 in Category 2 of the 503A interim bulks list 29 September 2023, then removed it 22 April 2026 following nomination withdrawal — this is not Category 1 placement. PCAC reviews “BPC-157 (free base) / BPC-157 acetate” on 23 July 2026; the arginate salt is not on the agenda. WADA prohibits BPC-157 under S0 at all times; TGA Schedule 4 + Appendix D.
  • Community Score 50 (Tier C); the rebrand wave dates to late-2023 with the Huberman Lab × Koniver episode (7 October 2024) as the canonical mainstream introduction. Adoption is heaviest in the telehealth / med-spa channel and the oral-capsule channel (Infiniwell, Wise Choice, ProHealth Longevity); grey-market injectable discourse uses “PDA” and “BPC-157 arginate” interchangeably with the acetate.
  • The central evidentiary asterisk is twofold: (1) PDA inherits the BPC-157 single-group dependency 🔴 in its entirety, including the active Sikirić/Seiwerth vs Józwiak dispute in Pharmaceuticals 2025; (2) the vendor claim of distinct mechanism / “>90% oral bioavailability” / “FDA-designated regenerative agent” is not supported by any indexed peer-reviewed publication or any FDA document.

1. Identity

FieldValueSource
Common namePentadeca Arginate (PDA); Penta Deca Peptide Arginate; BPC-157 arginate; pentadecapeptide arginate; “Arg-BPC”; “bepecin di-L-arginine salt”Vendor / patent nomenclature consolidated in [Patent — USPTO US9850282B2; WIPO WO2014142764A1]
Underlying peptideBody Protection Compound-157 (BPC-157); INN-investigated: bepecin; research codes PL-14736, PCO-02[Academic secondary source — PubChem CID 9941957]; [Clinical trial registry — NCT02637284]
Amino-acid sequenceH-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (GEPPPGKPADDAGLV)[Academic secondary source — PubChem CID 9941957]
Molecular formula (free peptide)C₆₂H₉₈N₁₆O₂₂[Academic secondary source — PubChem CID 9941957]
Molecular weight (free peptide)1419.5 Da[Academic secondary source — PubChem CID 9941957]
CAS — free peptide137525-51-0 (BPC-157, bepecin)[Academic secondary source — NCATS Inxight Drugs DRUG ID 8ED8NXK95P]
CAS — acetate salt1628202-19-6 (BPC-157 monoacetate)[Academic secondary source — NCATS Inxight Drugs DRUG ID PAR2FC72XP]; [Patent — USPTO US 11,833,189 B2]
CAS — arginate saltNo distinct CAS identified. No PubChem, DrugBank, USAN, INN, NCATS Inxight, or USP entry for the arginate as a separately registered substance.Direct primary-source search; [Patent — USPTO US9850282B2]
Salt-form chemistryL-arginine counter-ion bound non-covalently via ionic interaction with the peptide’s free carboxylates; preferred stoichiometry per the originator patent is 1:2 (peptide : L-arginine, di-L-arginine salt, “Arg-BPC”); 1:1 and 1:3 also disclosed. Not a covalent conjugation; not an extension of the 15-residue chain.[Patent — USPTO US9850282B2; WIPO WO2014142764A1, claims 1–15]
INN application statusNone identified for the arginate salt specifically; underlying peptide referenced under proposed INN “bepecin” in Diagen/PharmaCotherapia documentation; no WHO INN listingDirect primary-source search; [Clinical trial registry — NCT02637284]
ClassSynthetic pentadecapeptide salt (research / unapproved drug); marketed as compounded peptide and as research chemical[Regulatory document — DoD-OPSS BPC-157 page]; [Regulatory document — FDA 503A interim bulks list 2023-09-29]
Brand / trade names in commerce”Pentadeca Arginate Complex,” “PDA peptide,” “BPC-157 Arginate,” “Repair and Recovery” (with TB-4 fragment), “Stable BPC-157 Arginate,” “pentadeca short-chain amino acids” (Infiniwell rebrand)Named vendor channels; no FDA-approved trade name
Half-lifeNot characterised for the arginate salt in any peer-reviewed publication; no published terminal plasma half-life in humans for free peptide or acetate either[Clinical trial registry — NCT02637284, results not posted]

2. History and Development

The underlying pentadecapeptide BPC-157 was first described by Sikirić and Seiwerth at the University of Zagreb in the early 1990s as a fragment of human gastric juice “Body Protection Compound” [Peer-reviewed preclinical study — Sikiric P et al., Dig Dis Sci 1996;41(7):1518–26] 🔴. The L-arginine salt — “bepecin di-L-arginine salt” or “Arg-BPC” — was disclosed in a 2013 priority filing by Rudolf Rucman, assigned to Diagen d.o.o. (Slovenia), and granted in the United States as US9850282B2 on 26 December 2017, with international counterpart WO2014142764A1. The patent specifies salts of one molecule of pentadecapeptide with one, two, or three molecules of a basic amino acid (preferred: L-arginine, 1:2 stoichiometry) and reports accelerated-aging stability data at 50 °C and 65% relative humidity versus the acetate and trifluoroacetate forms.

The earliest registry trace of the underlying peptide in any oral human dosing protocol is NCT02637284 (PharmaCotherapia d.o.o., a Diagen affiliate), a 42-volunteer Phase 1a/1b oral safety-and-pharmacokinetics study of “PCO-02” (1 mg “bepecin” tablets) conducted at Hospital Ángeles Tijuana, planned for January–June 2015 [Clinical trial registry — NCT02637284]. The trial does not specify the salt form on the public record, used the development name “bepecin,” and has no posted results. Independent commentary has noted the absence of any subsequent registered study, publication, or Phase 2 progression [Peer-reviewed review — Józwiak M et al., Pharmaceuticals 2025;18:185].

The marketing identifier “Pentadeca Arginate” is not used in the originator patent (which uses “bepecin” or “Arg-BPC”) and is not used in the peer-reviewed BPC-157 literature. The term entered U.S. compounding-pharmacy and telehealth commerce in late 2023 / 2024 following FDA’s 29 September 2023 placement of BPC-157 on the 503A bulks list at Category 2. Mainstream propagation accelerated after the 27 February 2026 Joe Rogan Experience #2461 appearance by HHS Secretary Robert F. Kennedy Jr., in which 14 of 19 Category-2 peptides were stated to be reverting toward Category 1; the formal FDA notice removing 12 peptides (including BPC-157) from Category 2 due to withdrawn nominations was published 15 April 2026 with effect 22 April 2026 [Regulatory document — FDA / HHS notice, April 2026; PCAC meeting notice Federal Register 2026-07361].

A direct PubMed search for “pentadeca arginate” returns zero hits as of 15 May 2026. The identifier is a commercial coinage; the chemistry it describes traces to the 2013 Diagen patent.

3. Mechanism of Action

Demonstrated in humans

No mechanism-of-action data have been published for “pentadeca arginate” as a discrete entity in humans. The only registered human exposure study (NCT02637284) has not posted results [Clinical trial registry — NCT02637284]. Other “human” data referenced in vendor literature trace to two unpublished or under-reported Diagen / PharmaCotherapia early-phase studies on ulcerative-colitis enemas using bepecin / PL-14736, with no Phase 2 readout in the indexed peer-reviewed record.

Proposed / preclinical

Because the L-arginine counter-ion dissociates from the peptide in aqueous solution, the active species at the biological interface is the BPC-157 free peptide. Mechanisms therefore port over from the BPC-157 preclinical corpus, which is dominated by the Sikirić / Seiwerth / Diagen group (>80% of indexed BPC-157 publications) 🔴:

  • Pro-angiogenic signalling via VEGFR2, eNOS, and EGR-1 transcription [Peer-reviewed preclinical review — Seiwerth S et al., Curr Pharm Des 2018;24:1972–89] 🔴
  • Modulation of the nitric-oxide system, including counteraction of L-NAME-induced effects and interaction with L-arginine substrate availability [Peer-reviewed preclinical study — Zemba Cilic A et al., Behav Brain Res] 🔴
  • FAK–paxillin pathway activation, growth-hormone-receptor upregulation, and brain–gut axis modulation [Peer-reviewed preclinical review — Vukojević J et al., Neural Regeneration Research 2021;17(3):482–7] 🔴
  • Cytoprotective effect on gastric, hepatic, vascular, and tendon tissue [Peer-reviewed preclinical review — Sikiric P et al., Pharmaceuticals 2024;17:461] 🔴

Vendor claim of distinct mechanism

The central vendor claim — that “arginate uniquely enables oral bioavailability >90%” versus “<3% for the acetate form” — has not been substantiated in indexed peer-reviewed literature. The Diagen patent (US9850282B2) reports stability under accelerated aging and improved survival in simulated gastric juice for the di-L-arginine salt versus the acetate, but does not measure intestinal permeability, AUC, Cmax, or absolute oral bioavailability in vivo. The “90%” figure attributed to “the original patent holders” cannot be traced to the patent text or to any indexed publication. Gastric stability is a necessary but not sufficient condition for oral systemic exposure [Patent — USPTO US9850282B2, Examples; PubMed null-result on “BPC-157 arginate” pharmacokinetics].

The pharmacological contribution of the arginine counter-ion at clinical doses (250–1000 µg peptide; ≈0.06–0.25 mg L-arginine at 1:2 stoichiometry) is below threshold for any documented systemic L-arginine effect, which requires gram-scale dosing for NO-pathway modulation in humans.

4. Regulatory Status

Last regulatory review: 2026-05-15.

4.1 Drug-regulatory status

AuthorityActionDateSource-class
FDA — Drugs@FDANo approval. No NDA, BLA, IND publicly listed for “pentadeca arginate,” “BPC-157 arginate,” or “bepecin arginate.”n/a[Regulatory document — FDA Drugs@FDA database, accessed 2026-05-15]
FDA — 503A interim bulks listBPC-157 added to Category 2 (significant safety concerns; not eligible for 503A compounding). “Pentadeca arginate” and “BPC-157 arginate” are not separately listed; the listed entries are “BPC-157 (free base)” and “BPC-157 acetate.”2023-09-29[Regulatory document — FDA Interim 503A Bulks List update, 2023-09-29]
FDA — 503A bulks listTwelve peptides (including BPC-157) removed from Category 2 following withdrawal of nominations; this is not Category-1 placement. Arginate salt not separately addressed.2026-04-15 (notice) / 2026-04-22 (effective)[Regulatory document — FDA / HHS notice, April 2026]
FDA — Pharmacy Compounding Advisory Committee (PCAC)Meeting scheduled 23 July 2026 to evaluate “BPC-157-related bulk drug substances (BPC-157 (free base) / BPC-157 acetate)” for ulcerative colitis, alongside KPV, TB-500, MOTs-C. The arginate salt is not on the published PCAC agenda.2026-07-23[Regulatory document — FDA PCAC notice, Federal Register Docket FDA-2026-N-2979]
FDA — Warning letters / enforcementNo public FDA warning letter or import alert as of 2026-05-15 names “Pentadeca Arginate” or “BPC-157 arginate” specifically. FDA has issued 50+ warning letters to peptide compounders 2024–2025 referencing “BPC-157” generically; arginate-salt distinction is not invoked.through 2026-05-15[Regulatory document — FDA Warning Letter database search]
FDA / DOJ — Tailor Made Compounding LLC (EDKY)Guilty plea for distributing unapproved drugs including BPC-157; $1,788,906.82 forfeiture; lifetime prescription-drug ban for Jeremy Delk. Arginate not separately named in plea documents.2023 (plea)[Press release — DOJ EDKY, court-record-corroborated]
FDA / DOJ — Amino AsylumJune 2025 search-and-seizure; December 2025 plea (USAO Northern District of Indiana, United States v. Matthew Kawa et al.). BPC-157 named in indictment; “pentadeca arginate” not separately named.2025-06 / 2025-12[Press release — DOJ NDIN]
EMANo marketing authorisation; no CHMP opinion; no orphan designation for BPC-157 or any arginate-salt variant.n/a[Regulatory document — EMA database search]
MHRA — UKNot approved; not on the BNF; no public statement specifically on the arginate salt.n/a[Regulatory document — MHRA / BNF search]
TGA — AustraliaBPC-157 added to Schedule 4 (Prescription Only) of the Poisons Standard, with additional listing in Appendix D, clause 5 (possession without authority is illegal). Implementation 1 June 2024. The scheduling instrument refers to “BPC-157” by chemical identity; the arginate salt is not separately exempted and falls under the same entry as a matter of substance identity.2024-06-01[Regulatory document — TGA Notice of final decisions, Nov 2023 / June 2024]; [Regulatory document — Sport Integrity Australia BPC-157 page]
Health CanadaNot authorised; not on the DPD. Generic peptide advisories apply to BPC-157; arginate salt not separately addressed.n/a[Regulatory document — Health Canada DPD]
PMDA — JapanNot approved.n/a[Regulatory document — PMDA database]
NMPA — ChinaNot approved.n/a[Regulatory document — NMPA database]
MFDS — KoreaNot approved.n/a[Regulatory document — MFDS database]
GRLS — RussiaNo GRLS registration for BPC-157 or “bepecin arginate” identified.n/a[Regulatory document — GRLS database]
WHO Essential Medicines ListNot listed.n/a[Regulatory document — WHO Model List of Essential Medicines, 23rd Edition]

4.2 Anti-doping status

AuthorityActionSource-class
WADA Prohibited List 2024 / 2025 / 2026BPC-157 prohibited under S0 (Non-Approved Substances), at all times, in and out of competition. Specified Substance. No Therapeutic Use Exemption available. S0 class scope is defined by substance identity rather than salt form, so “BPC-157 arginate” is captured under the same S0 entry as a matter of construction. WADA has not issued a public statement carving out the arginate salt.[Anti-doping document — WADA 2024/2025/2026 Prohibited List S0]
WADA Monitoring Program”Pentadeca arginate” not separately listed; no public addition specific to the salt form.[Anti-doping document — WADA 2026 Monitoring Program]
USADA”BPC-157 is prohibited under WADA S0… not approved for human clinical use by any global regulatory authority.” Salt form not distinguished.[Anti-doping document — USADA BPC-157 athlete advisory]
NCAAInherits S0; banned by class as a non-FDA-approved substance under the NCAA Banned Drug Classes.[Anti-doping document — NCAA Banned Drug Classes 2025-26]
DoD-OPSS / Operation Supplement SafetyBPC-157 listed as “prohibited peptide and unapproved drug”; on the DoD Prohibited Dietary Supplement Ingredients List in accordance with DoDI 6130.06. Salt form not distinguished.[Regulatory document — DoD-OPSS BPC-157 article]
Global DROReflects WADA Prohibited status by jurisdiction. Check date: 2026-05-15.[Anti-doping document — Global DRO substance check]
BSCG (Banned Substances Control Group)Treats BPC-157 and analogue salt forms as prohibited.[Anti-doping document — BSCG 2026 peptide regulation update]
Sport Integrity Australia”BPC-157 is a prohibited substance listed under section S0… A Therapeutic Use Exemption would not be granted.”[Anti-doping document — Sport Integrity Australia BPC-157 page]
UK Anti-Doping / CCES (Canada)Inherit WADA S0; no separate public statement on the salt form identified.[Anti-doping document — UKAD / CCES databases]

Detection-window literature. No published mass-spectrometry assay distinguishes BPC-157 free base, acetate, and arginate in urine or blood. Detection in anti-doping samples relies on LC-MS/MS targeting the parent pentadecapeptide ion (≈1419.7 Da) and its tryptic fragments; counter-ion identity is not preserved in solution and is irrelevant to the analytical method. No sanction has been published in which “pentadeca arginate” is named separately from BPC-157.

4.3 Last regulatory review

Last regulatory review: 2026-05-15.

5. Formulations and Routes

Approved. None — no marketed authorised formulation in any jurisdiction.

Investigational. NCT02637284 used 1 mg oral tablets of “bepecin” (PCO-02), salt form unspecified [Clinical trial registry — NCT02637284]. No registered Phase 2/3 program for any salt form of BPC-157 has reported results.

Compounded (503A pharmacy channel — currently in regulatory transition). Subcutaneous injection vials at typical concentrations supporting 250–500 µg doses; compounded by 503A pharmacies under prescription. Prescription pathway depends on FDA’s post-22 April 2026 enforcement posture, which is still being clarified by the PCAC review scheduled for 23 July 2026.

Grey-market / research-chem channel. Lyophilised powder for reconstitution (Peptide Sciences, Real Peptides, SeekPeptides, and others); marketed as “BPC-157 Arginate Salt.” Reconstituted with bacteriostatic water for subcutaneous injection in community-circulated protocols.

Dietary-supplement-positioned oral capsules. This is the distinctively-PDA formulation channel. Infiniwell, Wise Choice Supplements, ProHealth Longevity, and Peptide Sciences (Repair and Recovery combination capsule) offer oral capsules at 250 µg or 500 µg per capsule, “as BPC-157 Arginate Salt,” some paired with Salcaprozate Sodium (SNAC) 1.5–3 mg as an absorption enhancer. Infiniwell rebrands the active label as “pentadeca short-chain amino acids” for dietary-supplement positioning.

Routes documented in community use. Subcutaneous injection (near-injury or systemic); oral capsule (rapid- or delayed-release). Intravenous bolus is mentioned in the Koniver podcast appearance as a “spark” combined with subcutaneous maintenance dosing.

6. Preclinical Evidence

The preclinical evidence base for “pentadeca arginate” as a discrete substance is essentially empty. PubMed, Embase, Scopus, and Google Scholar searches for “pentadeca arginate,” “BPC-157 arginate,” “pentadecapeptide arginate,” “bepecin arginate,” and “Arg-BPC” return no peer-reviewed primary-study hits as of 2026-05-15. The Diagen patent (US9850282B2) contains the only primary characterisation of the salt form:

  • Accelerated thermal stability: Arg-BPC (1:2) retained ≥99.4% of starting peptide content at 50 °C / 65% RH; the acetate form is reported as degrading substantially more under the same conditions [Patent — USPTO US9850282B2, Example tables] ⚠️ industry-funded; not peer-reviewed.
  • Simulated gastric juice stability: Patent reports improved survival of the di-L-arginine salt versus acetate in pepsin / acidic media [Patent — USPTO US9850282B2].
  • Solubility: Arg-BPC reported as “very well soluble in water”; pH of solution adjustable to 4.60 or 7.40 per claims [Patent — USPTO US9850282B2, claims 15–16].

No in vivo pharmacokinetic study (absolute oral bioavailability, AUC, Cmax, t½) of the arginate salt has been published in a peer-reviewed venue. No comparative efficacy study (arginate vs acetate vs free peptide) in any tissue-healing rodent model has been published.

All preclinical activity attributed to “PDA” in vendor literature in fact references the BPC-157 corpus, in which the salt form is overwhelmingly acetate or free peptide. That corpus has the following characteristics:

  • 190 PubMed-indexed records under “BPC 157” as of May 2025

  • 80% list Predrag Sikirić or Sven Seiwerth as first or senior author 🔴

  • Routine reliance on a narrow dose range (10 µg/kg and 10 ng/kg) [Peer-reviewed review — Józwiak M et al., Pharmaceuticals 2025;18:185]
  • Limited independent in vitro replication; no published independent in vivo replication of major efficacy claims [Peer-reviewed reply — Józwiak M et al., Pharmaceuticals 2025;18:1451]

Specific preclinical studies that explicitly used the arginate salt rather than acetate or free peptide: none identified in the peer-reviewed primary literature.

7. Clinical Evidence

No adequately powered human randomised controlled trial has been completed and published for any form of BPC-157, including the arginate salt. A registry search returns:

  • NCT02637284 — Phase 1 / pilot, 42 healthy volunteers, single-centre Tijuana, oral “PCO-02” (1 mg bepecin tablets, single and multiple ascending dose) vs placebo; sponsor PharmaCotherapia d.o.o.; first/last posted 22 December 2015; no results posted on ClinicalTrials.gov. Salt form not specified in the public record [Clinical trial registry — NCT02637284]. ⚠️ industry-funded; 🔴 single-group dependency.
  • No ClinicalTrials.gov record under “pentadeca arginate,” “BPC-157 arginate,” “bepecin arginate,” “Arg-BPC,” or “pentadecapeptide arginate.”
  • No EU CTIS, WHO ICTRP, ISRCTN, jRCT, ChiCTR, or ANZCTR record under the same terms.
  • Older PharmaCotherapia / Diagen ulcerative-colitis enema work on PL-14736 (Phase 1/2 era, early 2000s) has no published Phase 2 result indexed in PubMed [Peer-reviewed review — Józwiak M et al., Pharmaceuticals 2025;18:185].

No published human pilot study, retrospective case series, or pharmacokinetic study specifies the arginate salt as the dosed form. The single retrospective orthopaedic case series cited in 2024–2025 reviews used “BPC-157” without salt-form specification and was small, uncontrolled, and not arginate-specific [Peer-reviewed review — DeFoor MT, Dekker TJ, Arthroscopy 2025;41(2):150–2].

7.5 Disputed Claims

Three distinct disputes converge on PDA.

Dispute 1 — Distinct chemical entity vs L-arginine counter-ion salt of BPC-157. Vendor channels frame PDA as a structurally and pharmacologically distinct molecule warranting separate regulatory treatment from BPC-157. The primary-chemistry position is that “Pentadeca Arginate” describes a non-covalent salt of the same pentadecapeptide (GEPPPGKPADDAGLV), as defined explicitly in the originator patent: “Pentadecapeptide salts containing 2 mols of basic amino acids per 1 mol of pentadecapeptide… preferred is bepecin di-L-arginine salt (abbr.: Arg-BPC)” [Patent — USPTO US9850282B2]. Once dissociated in aqueous solution at physiological pH, the active species is the BPC-157 peptide; the counter-ion has no covalent bond to the peptide and is not part of its 15-residue sequence. No primary regulatory body has adjudicated whether the arginate salt is a separate substance for compounding purposes. FDA’s PCAC docket for July 2026 names only “BPC-157 (free base) / BPC-157 acetate,” leaving the arginate-salt status formally ambiguous in U.S. compounding doctrine; however, neither FDA nor TGA has issued any public statement endorsing the vendor framing that the arginate salt is outside the scope of the underlying BPC-157 designation. Healthcare-compounding legal commentary characterises the change-of-salt argument as legally weak under the “essentially a copy” doctrine, but this position has not been litigated.

Dispute 2 — Stability and oral bioavailability claims. Vendor language asserts that arginate enables “>90% oral bioavailability” versus “<3% for acetate.” The Diagen patent demonstrates stability (gastric-juice survival and accelerated-aging shelf life), not bioavailability in the pharmacokinetic sense (AUC, Cmax). No in vivo absolute oral bioavailability measurement of the arginate salt has been published in a peer-reviewed venue indexed in PubMed. The bioavailability claim is unsourced relative to the patent and absent from peer-reviewed literature.

Dispute 3 — The underlying Sikirić/Seiwerth vs Józwiak/Bauer/Kamysz/Kleczkowska dispute over BPC-157. PDA inherits this dispute in full. The Józwiak group’s review [Pharmaceuticals 2025;18:185, DOI 10.3390/ph18020185] raised concerns about pro-angiogenic/NO over-stimulation, single-group dominance of the literature (>80% Sikirić/Seiwerth), narrow dose range, and absence of independent in vivo replication of anti-tumour and neuroprotective claims. The Sikirić group’s comment [Pharmaceuticals 2025;18:1450, PMID 41155565] 🔴 defends safety (LD₁ not reached) and reframes the effects as “modulation” rather than over-stimulation. The Józwiak reply [Pharmaceuticals 2025;18:1451] notes that the cited toxicity studies were administered at 2 g/kg (≫ proposed clinical dose), reiterates the single-group concern, and observes that the anti-tumour claim rests on a single unreplicated 2004 melanoma cell-line experiment. This dispute is in active print and unresolved. Because PDA’s mechanism rationale is the BPC-157 mechanism rationale, every element of this dispute applies to PDA.

7B. Community Evidence Layer

Community context

PDA as a discrete community-named compound is a late-2023 → 2024 emergence that maps directly onto FDA’s September 2023 Category 2 designation of BPC-157 under the 503A bulks list. Before that designation, “BPC-157 arginate” appears only sporadically in research-chemistry contexts (Diagen / Rucman patent, 2013–2017). The acceleration into community vocabulary is post-FDA.

The canonical mainstream introduction is the Huberman Lab podcast episode with Dr. Craig Koniver, “Peptide & Hormone Therapies for Health, Performance & Longevity,” 7 October 2024. Koniver tells Huberman: “There’s a new compound, newer, a peptide called the short for PDA, Pentadeca Arginate. It’s basically the same molecular structure as BPC, except they’ve swapped out an acetate for arginate… One amino acid substitution.” The “one amino acid substitution” framing is factually incorrect — arginate is a counter-ion, not an amino-acid substitution — and that error has propagated downstream into multiple clinic pages. Huberman explicitly tells the audience: “let’s put that on people’s ear map, brain map. Pentadeca arginate may be a good physician-prescribed substitution for people that can benefit from BPC-157.”

Sub-community adoption in observed order of arrival: (1) telehealth / med-spa / wellness-physician channel first (Koniver Wellness, The Piazza Center × Celia Health “Snapback Stack,” Wittmer, Aspire Health, Vita Bella, All U Health, IAM, Pinnacle Performance Labs, Paragon Sports Medicine and others); (2) affiliate-flagged biohacker blogs (Brainflow, PeptideDeck, PeptideFox, PeptideInsight, peptides.org, PDA Peptide .com, SeekPeptides); (3) dietary-supplement repackaging (Infiniwell’s “pentadeca short-chain amino acids” rebrand, ProHealth Longevity, Wise Choice Supplements, TheaWell); (4) research-chem / grey-market last and thinnest, where the rebrand has not displaced the acetate in injectable discourse.

Documented protocols

#SourceDateDoseFrequencyCycleRouteNotes
1Dr. Craig Koniver on Huberman Lab (Koniver Wellness operates a peptide telehealth practice)7 Oct 2024250–500 µg (“we’re using 500 µg”)Once daily, M–F, weekends offMulti-week, not explicitly boundedSubcutaneous (also IV bolus + SQ “spark + maintenance”)Pairs at bedtime with ipamorelin / tesamorelin
2PeptideFox “BPC-157 & PDA” page (independent-style blog with vendor links)retrieved May 2026250–750 µg SQ near injury, OR 500 µg oral 2×/day for gut healingDaily4–8 weeksSQ or oral capsuleCites $325–400 per 15 mg vial through telehealth-enabled compounding
3Infiniwell BPC Rapid Pro / Delayed Pro (vendor; affiliate codes IW15 / BRAINFLOW)retrieved May 2026250 µg or 500 µg per capsule (as “BPC-157 Arginate Salt”) + SNAC 1.5–3 mg1 capsule 2×/dayOpen-ended subscriptionOral capsule (rapid- or delayed-release)Marketed as “pentadeca short-chain amino acids”
4Wise Choice Supplements “BPC-157 Dosage Guide 2026” (vendor — BPC-157 Arginate 500 µg, 120 ct, $104.99)2026500 µg per capsule; lower end of standard range if switching from acetateDaily, often 1–2×Open-endedOral capsule”Janoshik third-party tested”
5Peptide Sciences “Repair and Recovery” 60 ct (research-chem / vendor)retrieved May 2026Stable BPC-157 Arginate + Ac-SDKP (TB-4 fragment) per capsuleOne daily, empty stomach4–8 weeksOral capsule (combo)Only widely-cited pre-blended PDA + TB-4 oral capsule
6The Piazza Center × Celia Health “Snapback Stack” (telehealth + plastic-surgery clinic partnership)retrieved May 2026Not publicly disclosed pre-consult; personalisedPersonalisedTied to pre/post-surgical windowMix of SQ injectable + Infiniwell BPC-LX Pro oral sprayPrescription / “good faith medical screening” framing
7PeptideFox / PeptideDeck synthesis (affiliate-flagged biohacker blogs)2025–2026500 µg arginate oral BID for gut; 250–500 µg SQ for tendon/MSKDaily4–8 weeksOral or SQPosition oral as gut-specific, injectable as systemic / MSK
8Vita Bella PDA Dosage Guide (telehealth)retrieved May 2026SQ: lower µg; Oral: higher mg, “maintenance not acute repair”DailyNot specifiedSQ or enteric-coated oralDistinguishes oral as maintenance vs SQ as acute

The injectable PDA protocol numerically duplicates the BPC-157 acetate envelope (250–500 µg SQ). The only genuinely novel PDA-specific protocol is oral capsule dosing at 500 µg 1–2× daily, which depends almost entirely on the pH-3 stability claim and on SNAC-enhanced absorption.

Claimed effects

  • “Same therapeutic profile as BPC-157 (tendon, ligament, gut, anti-inflammatory, angiogenesis)” — universal across all retrieved sources — top-cited: Koniver on Huberman Lab.
  • “Improved oral bioavailability / survives gastric acid” — widespread across vendor / clinic pages — top-cited: PeptideFox citing the Diagen patent’s HPLC data (“93% stable at pH 3.0” vs ~7.8% for acetate). The trace is to a 2013 patent, not to independent peer review.
  • “More stable in storage / longer shelf life” — common — top-cited: PeptideInsight, Wise Choice Supplements.
  • “Gut-targeted / better for leaky gut, IBS, NSAID-induced GI damage” — common — top-cited: PeptideFox, Aspire Health.
  • “Enhanced nitric oxide / circulation effect from the arginine counter-ion” — common in vendor copy — top-cited: You Beauty Lounge, Paragon Sports Medicine, IAM Clinic. This claim has no controlled-study support; the arginine moiety is stoichiometrically small relative to a meaningful NO-precursor dose.
  • “Superior collagen synthesis / faster tendon healing than acetate” — common in clinic copy — top-cited: All U Health, Aspire Rejuvenation, Paragon Sports Medicine. No head-to-head clinical comparison exists.
  • “Legal / FDA-compliant alternative to BPC-157” — widespread across telehealth — top-cited: Amazing Meds (“PDA has been designated by the FDA as a regenerative agent”), Wittmer Rejuvenation. This claim is contested and largely inaccurate; PeptideFox and PeptideInsight both note the FDA has not separately listed PDA, that a salt-form change does not legally differentiate the molecule under the “essentially a copy” doctrine, and that WADA’s S0 prohibition covers all salt forms.
  • “Approved by FDA as a regenerative agent” — appears verbatim across at least three clinic sites (Wittmer, Amazing Meds, several telehealth pages) — this claim is false. No FDA approval, designation, or guidance document treats PDA as a regenerative agent. It is a recurrent vendor-copy meme.

Reported side effects

  • Mild injection-site reactions (redness, bruising, itching) — common — Aspire Health side-effects guide — vendor; framed as “process, not peptide.”
  • Mild GI changes / transient bloating / bowel-habit shift on oral capsules — common in the oral channel only — Aspire Health, Simply Wellness — vendor.
  • Headaches / mild dizziness shortly after dose — occasional — Simply Wellness, Aspire Health — vendor.
  • “Oral arginate did nothing for me / underdosed” — the dissenting countercurrent. Frequency cannot be quantified without retrievable Reddit thread access; acknowledged indirectly even in vendor-friendly material — Brainflow’s BPC-157 oral-vs-injection comparison concedes “real-world results for gut healing are not as impressive as you might expect” and “most users report better results with injectable for nearly everything.” This is the most important PDA-specific negative pattern: the oral capsule format — which is the distinctive PDA SKU vs BPC-157 acetate — is the one most prone to “I didn’t feel anything” reports.
  • “Weaker effect than acetate injectable” — occasional, anecdotal — sourcing thin; community sentiment without retrievable named-thread anchor.
  • No serious adverse events documented in any retrieved community source. PDA-specific serious-AE reporting infrastructure (FAERS-style) does not exist; absence of reports ≠ absence of events.

Community dissent — the central PDA dispute

The optimisation community is split into roughly three positions, and unlike most compounds the split is primarily about identity, not effect.

Camp A — “PDA is a genuinely distinct / superior molecule.” Proponents: Koniver (Huberman Lab, framing it as “one amino acid substitution” — factually wrong but influential); telehealth-clinic blogs (Wittmer, Amazing Meds, Aspire Health, Aspire Rejuvenation, Vita Bella, All U Health, Elase, Paragon Sports Medicine, You Beauty Lounge, IAM, Pinnacle Performance Labs); SeekPeptides “complete guide” and PDA Peptide (.com); Infiniwell’s “pentadeca short-chain amino acids” rebrand. Talking points: enhanced stability, oral bioavailability, “FDA regenerative agent” designation, distinct regulatory status, distinct CAS treatment in compounding contexts.

Camp B — “PDA is the L-arginine salt of BPC-157; the rebrand is a regulatory and commercial manoeuvre.” Proponents: PeptideFox (“PDA is BPC-157 with a different salt form, defined in a 2013 patent… The peptide sequence is identical”); PeptideInsight (“The salt form (arginate vs. acetate) does not alter this classification” under FDA/WADA); the Diagen / Rucman patent itself; independent peptide-law analyses cited by PeptideFox (“a salt-form change does not create meaningful legal differentiation under the ‘essentially a copy’ doctrine”); Wise Choice Supplements’ own dosage guide which concedes the foundational research was on acetate. Camp B further notes that no published PubMed result exists for “pentadeca arginate” as a distinct entity.

Camp C — “It’s basically BPC-157, who cares, just dose it.” This appears to be the dominant grey-market / r/Peptides / bodybuilding-forum sentiment as best as can be inferred from the indirect signals available. Direct Reddit thread-level evidence was not retrievable in Pass 2 — see retrieval limitations below. Symptomatic of this camp: vendors selling injectable powder list “BPC-157 Arginate Salt” and “BPC-157 acetate” side by side at similar prices without claiming clinical superiority.

Infiniwell’s adoption of the non-peptide-sounding label “pentadeca short-chain amino acids” — and its explicit on-site disclosure that this is a “more responsible standard” because “BPC-157” is “research classification” — is the cleanest example of vendor-driven re-naming for regulatory positioning.

Stack patterns

  • “Wolverine Stack” (PDA + TB-500). Adopted directly from the BPC-157 + TB-500 canon. Elase Med Spa explicitly labels its offering “the Wolverine Stack.” Peptide Sciences’ Repair and Recovery capsule (BPC-157 Arginate + Thymosin Beta-4 fragment Ac-SDKP) is the only widely-cited pre-blended oral product in this category.
  • Koniver bedtime growth-axis stack. Koniver describes combining PDA with ipamorelin and tesamorelin/sermorelin in a single bedtime subcutaneous injection, M–F, weekends-off rationale ported from legacy growth-hormone dosing schedules.
  • GLP-1 GI-mitigation stack. Telehealth pages (Aspire Health, Vita Bella, Celia Health-adjacent) and biohacker blogs (PeptideFox) document use of oral PDA capsules concurrently with semaglutide / tirzepatide / retatrutide to mitigate GLP-1 / GIP GI side effects. The mechanistic argument is pH-stability + gut-targeted framing; the evidence is anecdotal. This is a genuinely PDA-specific use case (the acetate is harder to dose orally) and may partly explain telehealth adoption velocity in the saturated GLP-1 market.
  • Snapback Stack (Piazza × Celia). Pre/post-surgical recovery stack built around PDA plus Infiniwell BPC-LX Pro oral spray plus peptides selected via “biomarker DNA genetic testing.” Marketed at plastic-surgery clientele.
  • KPV co-formulation. Infiniwell sells a “BPC + KPV” product for histamine-mediated / mast-cell presentations.

Vendor and supply context

Three distinct vendor channels:

  • Research-chem / injectable powder: Peptide Sciences (sells BPC-157 Arginate and the Repair and Recovery combo), Real Peptides, SeekPeptides, Annular, ProHealth Longevity, TheaWell, Pinnacle Performance Labs. Standard “not for human use” framing.
  • Oral capsule (distinctively PDA): Infiniwell (BPC Original / Rapid / Rapid Pro / Delayed / Delayed Pro lines at 250 or 500 µg per capsule, paired with SNAC; “pentadeca short-chain amino acids” labelling), Wise Choice Supplements (500 µg × 120 ct at $104.99, “Janoshik third-party tested”), ProHealth Longevity (500 µg, triple-tested framing), Peptide Sciences Repair and Recovery.
  • Telehealth-supervised: Koniver Wellness, Celia Health × Piazza Center, Wittmer Rejuvenation, Aspire Health, Aspire Rejuvenation (Pittsburgh, Dallas), Vita Bella, Elase Med Spa, All U Health, You Aesthetics, Intercoastal Health, IAM Clinic, Simply Wellness, Amazing Meds, Paragon Sports Medicine, Liquid Mobile IV.

Price. Oral capsules: $0.87–$2.67 per cap; per-day cost $1.70–$5. Injectable compounded vials via telehealth: ~$325–400 per 15 mg vial — roughly 5–10× the historic pre-ban price of BPC-157 acetate from research-chem suppliers. The premium pays for the prescription pathway and “physician oversight” framing.

Affiliate-marketing layer. Brainflow (IW15 / BRAINFLOW codes), PeptideDeck affiliate roundups, PeptideFox (more sceptical but still linked-vendor), SeekPeptides as long-form SEO sales copy, PDA Peptide .com as a domain-name-as-marketing portal. Practitioner-recommendation pages function as advertorial without explicit affiliate disclosure where the clinic sells the product directly.

QC structural concern. No public PDA-specific COA-fraud scandal surfaced. The “is it actually arginate-salt or are they shipping the acetate and calling it arginate” risk is structurally unresolved: no end-user assay distinguishes the two salt forms in the field, and the active peptide is identical, so a substituted product would still “work” for users in line with BPC-157 evidence.

Community Score: 50 (Tier C). Component breakdown: Usage volume 17 / 25; Protocol codification 15 / 25; Reported effect consistency 11 / 25; Time in circulation 7 / 25.

8. Safety Profile

Safety data specific to the arginate salt in humans: none. The only published human-exposure record on the underlying peptide is the unposted NCT02637284 Phase 1 (oral “bepecin” 1–6 mg, healthy volunteers); no adverse-event tabulation has been released. BPC-157 generic safety data (rodent LD₁ not reached at 2 g/kg per Sikirić; in vitro and ex vivo lack of overt toxicity at customary doses) ports to PDA to the extent the molecule in vivo is the same [Peer-reviewed preclinical study — Sikiric P et al., Pharmaceuticals 2025;18:1450, PMID 41155565] 🔴.

Salt-form-specific considerations. At 1:2 peptide-to-arginine stoichiometry and 250–1000 µg peptide dosing, the L-arginine counter-ion load is ≈60–250 µg per dose — far below any pharmacologically meaningful arginine exposure. Excipient profile of marketed PDA capsules is not characterised in the patent text; commercial preparations are 503A-compounded and not subject to FDA finished-drug review, so sterility, endotoxin, and content-uniformity testing rely on the compounder. No FDA tox package; no GLP repeat-dose toxicology in any species filed publicly.

Inherited class concerns from BPC-157:

  • Pro-angiogenic / VEGFR2 signalling raises a theoretical tumour-acceleration concern flagged in the Józwiak review and not rebutted with in vivo human or replicated rodent tumour-progression data [Peer-reviewed review — Józwiak M et al., Pharmaceuticals 2025;18:185].
  • No long-term (>2 weeks) human safety data of any kind.
  • No reproductive, developmental, genotoxicity, or carcinogenicity studies published.
  • No drug–drug interaction screen.

9. Drug Interactions

No interaction studies have been published for PDA / BPC-157 arginate. Interactions inherited from BPC-157 are theoretical only: potential interaction with the L-arginine / NO axis (additive vasodilator effect), with VEGF-pathway agents, and with growth-factor-modulating agents. No CYP-mediated interactions are characterised because no clinical PK data exist. No interaction with anticoagulants, antiplatelet agents, or immunosuppressants has been studied [absence-of-evidence statement; PubMed null result for “BPC-157 drug interaction” pharmacokinetic studies in humans].

10. Research Gaps

  • No published peer-reviewed pharmacokinetic comparison of arginate vs acetate vs free-base BPC-157 in humans.
  • No published bioavailability study of oral PDA capsules in humans or in any in vivo animal model with absolute-bioavailability methodology.
  • No human RCT specifically on the arginate salt form for any indication.
  • No independent (non-Sikirić, non-Diagen) replication of the underlying BPC-157 efficacy claims in adequately powered in vivo models.
  • No published mass-spectrometry assay differentiating the three salt forms in regulatory anti-doping context.
  • No long-term safety data of any kind (>2 weeks human exposure).
  • No FDA, EMA, MHRA, or PMDA toxicology package.
  • No published clinical trial under the identifier “pentadeca arginate” or “BPC-157 arginate” in any registry.
  • No CAS number, INN, USP monograph, or USAN entry for the arginate salt as a distinct substance.
  • No published in vivo demonstration that the arginine counter-ion confers pharmacological behaviour distinct from acetate or free peptide once dissociated.

11. Bottom-Line Encyclopedia Note

Pentadeca Arginate is the L-arginine salt of the 15-amino-acid BPC-157 peptide (GEPPPGKPADDAGLV), formally described as “bepecin di-L-arginine salt” in the 2013 Diagen originator patent (US9850282B2). Once dissociated in solution, the active species is identical to BPC-157; no distinct CAS, INN, or peer-reviewed pharmacokinetic profile separates the arginate from BPC-157 free base or acetate. Vendor claims of distinct mechanism, “>90% oral bioavailability,” and exemption from BPC-157’s regulatory framing are not supported by independent peer-reviewed evidence as of 15 May 2026. WADA S0 prohibition applies; FDA Category-2 framing applied to the underlying peptide through April 2026, with PCAC review of the free base and acetate scheduled 23 July 2026 (arginate not on the agenda). Therapeutic claims rest on the BPC-157 evidence base, which is single-group-dominated 🔴 and lacks adequately powered human RCTs.

11B. Gap Analysis

Pattern: Low science (E/0) × Medium community (C/50) — community fabricating a distinction.

This is a structurally different pattern from BPC-157’s D/A “community ahead of science.” There, the community had a 15-year codified protocol and a thick preclinical literature that simply hadn’t graduated to controlled human trials. Here, the community has invented a distinction — between PDA and BPC-157 acetate — that the chemistry and the regulatory record do not support.

The substantive gaps:

  • Science gap: there is no PDA-specific science. Every peer-reviewed citation a vendor or clinic invokes is BPC-157 acetate or free-peptide data. The salt-form claim is the only foothold for product differentiation and it is propped up entirely by one stability section of a 2013 patent. The Pass 1 score is E/0, not because PDA has been disproven, but because PDA-as-a-distinct-substance has never been tested.
  • Community gap: the central community claim is unverifiable. The “PDA is different” framing rests on three unsubstantiated assertions — superior oral bioavailability, distinct regulatory status, and “FDA regenerative agent designation.” The third is demonstrably false. The first has no peer-reviewed support. The second is contradicted by FDA and TGA scheduling, which treat BPC-157 by chemical identity rather than salt form.
  • Knowledge architecture problem. The community discourse and the regulatory record use different names for the same molecule — “pentadeca arginate” in vendor channels, “BPC-157” or “BPC-157 (free base) / BPC-157 acetate” in FDA and WADA documents. Readers comparing the two streams without the chemistry context will conclude PDA and BPC-157 are different substances. They are not.

The community-vs-regulatory naming gap is the single most consequential editorial finding in this monograph. It explains why telehealth clinics can claim “FDA-compliant alternative” without legal blowback (the FDA hasn’t named the salt) and why grey-market injectable users treat PDA and acetate interchangeably (they correctly perceive the chemistry).

The Pass 2 retrieval limit on Reddit thread-level evidence (see Section 13) means Camp C (“it’s basically BPC-157”) sentiment is documented indirectly through Brainflow’s review-aggregation concessions and through vendor pricing parity in the research-chem channel, rather than through direct community threads. This is a methodological gap acknowledged in the source list rather than a substantive uncertainty about whether the Camp C sentiment exists — Brainflow’s own concession that “real-world results for gut healing are not as impressive as you might expect” is the most defensible indirect anchor.

12. Three Paths

Definition, not prescription.

Conservative path. Gates: peer-reviewed publication of a Phase 2 RCT on the arginate salt specifically; FDA approval or favourable Category-1 PCAC determination (currently unavailable — PCAC will review the free base and acetate on 23 July 2026, not the arginate); independent replication of the underlying BPC-157 efficacy claims outside the Sikirić/Seiwerth/Diagen lineage; long-term human safety data beyond two weeks of exposure. The compound meets none of these gates as of 15 May 2026.

Moderate path. Treat the substance at its current tier — E/0 on science, C/50 on community — meaning: acknowledge no controlled human evidence, no FDA approval, an active WADA prohibition, a still-uncertain U.S. compounding pathway post-April 2026, and a vendor-driven distinction from BPC-157 that the chemistry doesn’t sustain. Anyone considering use would baseline at minimum a full lipid panel, hepatic panel, complete blood count, and (given the pro-angiogenic theoretical concern) explicit screen for current malignancy or recent malignancy history. Monitoring cadence to match the duration of any community-circulated protocol. Supply channel: 503A compounding pharmacy with prescription (if the post-April 2026 enforcement posture continues to permit this) carries different risks from research-chem powder (no compounder accountability, no chain-of-custody on identity).

High-tolerance path. Acknowledge that no evidentiary gates are met. Community mitigation patterns documented in Pass 2: third-party COA verification at the brand level (Janoshik, Eurofins) rather than per-batch — which does not actually confirm arginate-vs-acetate identity; slower titration than headline community doses; oral-route preference (where SNAC-enhanced absorption is plausible but unmeasured) is the only PDA-specific pattern with a distinguishing rationale; concurrent professional monitoring with bloodwork at a cadence appropriate to the cycle length; explicit acknowledgement that the WADA S0 prohibition extends to the salt form regardless of vendor framing. Anti-doping detection makes no distinction between BPC-157 salt forms; a positive test would be a positive test.

13. Key References

Science layer (Pass 1)

  • [Patent — USPTO US9850282B2] Rucman R / Diagen d.o.o. Stable pentadecapeptide salts. Priority 2013-03-13; granted 2017-12-26.
  • [Patent — WIPO WO2014142764A1] Same family, international filing.
  • [Patent — USPTO US 11,833,189 B2] Sublingual semaglutide–BPC 157 combination; cites BPC-157 acetate CAS 1628202-19-6 and BPC-157 arginate by name.
  • [Patent — EP 0572688; USPTO US 6,268,346; EP 0983300; USPTO US 6,288,028] Earlier BPC-157 synthesis and salt patents (Sikirić/Diagen lineage).
  • [Academic secondary source — PubChem CID 9941957] BPC-157, free peptide; C₆₂H₉₈N₁₆O₂₂; MW 1419.5.
  • [Academic secondary source — NCATS Inxight Drugs] BPC-157 (DRUG ID 8ED8NXK95P) and BPC-157 acetate (DRUG ID PAR2FC72XP).
  • [Clinical trial registry — NCT02637284] PCO-02 (bepecin) Phase 1 oral safety/PK, healthy volunteers, Tijuana 2015; no results posted.
  • [Peer-reviewed review — Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals 2025;18:185, DOI 10.3390/ph18020185.]
  • [Peer-reviewed comment — Sikirić P et al., BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions… Pharmaceuticals 2025;18:1450, DOI 10.3390/ph18101450, PMID 41155565.] 🔴
  • [Peer-reviewed reply — Józwiak M et al., Pharmaceuticals 2025;18:1451, DOI 10.3390/ph18101451.]
  • [Peer-reviewed review — Seiwerth S, Rucman R et al., BPC 157 and standard angiogenic growth factors. Curr Pharm Des 2018;24:1972–89.] 🔴
  • [Peer-reviewed review — DeFoor MT, Dekker TJ. Injectable therapeutic peptides — an adjunct to regenerative medicine and sports performance? Arthroscopy 2025;41(2):150–2.]
  • [Peer-reviewed preclinical study — Sikiric P et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis… Dig Dis Sci 1996;41(7):1518–26.] 🔴
  • [Regulatory document — FDA Interim 503A Bulks List update, 2023-09-29] BPC-157 added to Category 2.
  • [Regulatory document — FDA / HHS notice, April 2026] Twelve peptides including BPC-157 removed from Category 2; effective 2026-04-22.
  • [Regulatory document — FDA PCAC meeting notice, Federal Register Docket FDA-2026-N-2979] Agenda 23 July 2026: “BPC-157 (free base) / BPC-157 acetate.”
  • [Regulatory document — TGA Notice of final decisions to amend Poisons Standard, Nov 2023 / June 2024] BPC-157 Schedule 4 + Appendix D, clause 5; implementation 2024-06-01.
  • [Regulatory document — DoD-OPSS BPC-157 article]
  • [Regulatory document — Sport Integrity Australia BPC-157 page] S0 prohibited; no TUE.
  • [Anti-doping document — WADA 2024/2025/2026 Prohibited List, S0 Non-Approved Substances] BPC-157 explicitly named.
  • [Anti-doping document — USADA BPC-157 athlete advisory.]
  • [Press release — DOJ EDKY, United States v. Tailor Made Compounding LLC / Jeremy Delk.] $1.79M forfeiture for distribution of unapproved drugs including BPC-157.
  • [Press release — DOJ USAO Northern District of Indiana, United States v. Matthew Kawa et al. (Amino Asylum), 2025-06 raid / 2025-12 plea.]

Community layer (Pass 2)

  • Huberman Lab Podcast — Dr. Craig Koniver, “Peptide & Hormone Therapies for Health, Performance & Longevity,” 7 October 2024.
  • PeptideFox — “BPC-157 & Pentadeca Arginate (PDA)” — Camp B anchor.
  • PeptideDeck — “Where to Buy BPC-157 Arginate (Oral BPC-157): Best Vendors 2026.”
  • PeptideInsight — “BPC-157 Arginate.”
  • SeekPeptides — “Penta deca peptide arginate: the complete guide to BPC-157 arginate salt.”
  • Wise Choice Supplements — BPC-157 Dosage Guide 2026 and Brand Facts JSON.
  • Infiniwell — BPC Original / Rapid Pro / Delayed Pro product pages; “How to Choose the Right BPC-157 Peptide” blog.
  • Peptide Sciences — “Repair and Recovery (60 Capsules) – Stable BPC-157 Arginate, Thymosin Beta-4 Fragment.”
  • peptides.org — “BPC-157 Nasal Spray vs. Injections”; “BPC-157 + TB-500 Capsules: A-Z Guide.”
  • Brainflow — Infiniwell BPC-157 Rapid Pro review; “5 Best BPC-157 Supplements in 2026”; “BPC-157 Oral vs Injection.”
  • Aspire Health, Aspire Rejuvenation, The Piazza Center × Celia Health, All U Health, Wittmer Rejuvenation, Simply Wellness, Amazing Meds, Vita Bella, Elase Med Spa, You Beauty Lounge, IAM Clinic, Pinnacle Performance Labs, Paragon Sports Medicine, Intercoastal Health — telehealth and clinic vendor pages.

Retrieval limitations (Pass 2 substantive disclosure)

Direct Reddit thread-level evidence on PDA was not retrievable at title + permalink + date + claim resolution within the available retrieval window. Pushshift is effectively defunct; Wayback / archive.org Reddit caching was not exhausted within budget. No Reddit permalinks, vote counts, or thread titles are quoted in this monograph to avoid fabrication. Inferences about Reddit sentiment (Camp C “it’s basically BPC-157,” “oral arginate underdosed” countercurrent) rely on indirect signals — Brainflow’s review-aggregation, vendor-page testimonial dissonance, and the BPC-157 community baseline established in the separate BPC-157 monograph. Discord / Telegram peptide channels not indexed. MESO-Rx, EliteFitness, Anabolic Minds, ProMuscle threads specifically discussing the arginate salt not retrieved at thread resolution. Derek MorePlatesMoreDates / Ben Greenfield / Layne Norton / Peter Attia / Rhonda Patrick PDA-specific commentary not surfaced. Per-product COA-level detail for Wise Choice, ProHealth Longevity, TheaWell, Annular, Real Peptides not opened at per-batch resolution.

14. Audit / Refresh Trail

  • Composed: 2026-05-15
  • Pass 1 source file: pentadeca-arginate_sci_2026-05-15_E0.md (from-scratch creation; no prior PDA monograph in project knowledge)
  • Pass 2 source file: pentadeca-arginate_com_2026-05-15_C50.md
  • Last regulatory review (Section 4.3): 2026-05-15
  • Two-molecule calibration block status: Not applied. PDA is one molecule (the same pentadecapeptide GEPPPGKPADDAGLV with an arginate counter-ion that dissociates in aqueous solution). The naming-ambiguity layer is vendor-driven framing, addressed in Section 7.5 Dispute 1; it is not structural identity ambiguity between two different molecules (the TB-500 case).
  • Triggers for the next refresh:
    • PCAC determination on BPC-157 (free base / acetate) at the 23 July 2026 meeting and any subsequent FDA action explicitly addressing or omitting the arginate salt
    • Any FDA warning letter or enforcement action naming “pentadeca arginate” or “BPC-157 arginate” specifically
    • Publication of any peer-reviewed in vivo pharmacokinetic study comparing arginate vs acetate vs free-base BPC-157 bioavailability
    • Any new entry in the Pharmaceuticals 2025 exchange (Sikirić ↔ Józwiak) or comparable peer-reviewed dispute
    • Independent (non-Sikirić, non-Diagen) replication of BPC-157 efficacy in adequately powered in vivo models
    • WADA Prohibited List 2027 changes (annual cycle, October 2026 publication)
    • TGA scheduling change addressing the arginate salt separately
    • Major shift in vendor / telehealth landscape (Infiniwell, Koniver Wellness, Celia Health × Piazza Center) — discontinuation, FDA action, or platform-level reclassification
    • Joe Rogan Experience or comparable mainstream propagation event amplifying or retracting the “FDA regenerative agent” claim